Financial News

Geron Continues Climbing

Shares of Geron Corp. (NYSE: GERN) continued climbing by rising another 67 cents to $6.30 after the Food and Drug Administration cleared the biopharmaceutical to begin testing embryonic stem cell treatments on humans.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info